← Leaderboards
Seema Khan
Northwestern University At Chicago
$8,985,480
Attributed
$8,985,480
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.2M · FY2016–23$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$8,985,480 · 1
By mechanism
N01$8,985,480 · 1
Top collaborators
No co-investigators on record.
Most similar at Northwestern University At Chicago
Same institution · by research overlap
- Qiang Wen$670,316
- Barbara M Buttin$243,158
Others in their field
Top investigators on “Woman”
- Chanza Baytop · Westat, Inc.$271,217,917
- Lawrence Corey · Fred Hutchinson Cancer Center$252,110,127
- Wafaa M. El-Sadr · Columbia University Health Sciences$232,152,340
- Myron S Cohen · Family Health International$208,921,087
- Barbara Driver · Westat, Inc.$190,429,693
- Judith S. Currier · University Of California Los Angeles$149,317,678
Research focus
WomanMalignant NeoplasmsPlacebosDosePrimary EndpointSitePreventiveDiagnosisBiological MarkersSafetyClinical TrialsRecurrenceLiverContractorVisitPrimary Carcinoma Of The Liver CellsBreastParticipantSamplingMaintenanceBiologicalInfrastructureInterestLaboratory Experiment
Grant awards (25)
CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH$73,029
N01 · FY2023 · CA · contact PI
CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH$384,492
N01 · FY2022 · CA · contact PI
A phase I single-arm, multicenter pilot study aimed at validating y-OHPdG as a biomarker and testing the effects of Polyphenon E on its levels in patients with cirrhosis$142,069
N01 · FY2022 · CA · contact PI
CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH$426,812
N01 · FY2021 · CA · contact PI
EVALUATING INTERMITTENT DOSING OF ASPIRIN FOR COLORECTAL CANCER PREVENTION$226,821
N01 · FY2021 · CA · contact PI
OT::IGF::OT A phase I single-arm, multicenter pilot study aimed at validating y-OHPdG as a biomarker and testing the effects of Polyphenon E on its levels in patients with cirrhosis$142,069
N01 · FY2021 · CA · contact PI
IGF::OT::IGF IMMUNOGENICITY OF NONAVALENT HPV VACCINE ADMINISTERED PRIOR TO LIVING DONOR RENAL TRANSPLANTATION IN ADULT WOMEN: A PROSPECTIVE, SINGLE-ARM, MULTI-CENTER CLINICAL TRIAL$31,613
N01 · FY2021 · CA · contact PI
CONTRACT TITLE - CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH$637,416
N01 · FY2020 · CA · contact PI
EVALUATING INTERMITTENT DOSING OF ASPIRIN FOR COLORECTAL CANCER PREVENTION$600,700
N01 · FY2020 · CA · contact PI
Phase I trial of Endoxifen Gel Versus Placebo Gel in Women Undergoing Breast Surgery$206,138
N01 · FY2020 · CA · contact PI
IGF::OT::IGF STATIN THERAPY TO REDUCE DISEASE PROGRESSION FROM LIVER CIRRHOSIS TO CANCER$162,356
N01 · FY2020 · CA · contact PI
PHASE IIB TRIAL OF NEOADJUVANT ORAL TAMOXIFEN VERSUS TRANSDERMAL 4-HYDROXYTAMOXIFEN IN WOMEN WITH DCIS OF THE BREAST$111,986
N01 · FY2020 · CA · contact PI
CONTRACT TITLE - CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH$637,977
N01 · FY2019 · CA · contact PI
PHASE IIB TRIAL OF NEOADJUVANT ORAL TAMOXIFEN VERSUS TRANSDERMAL 4-HYDROXYTAMOXIFEN IN WOMEN WITH DCIS OF THE BREAST$601,680
N01 · FY2019 · CA · contact PI
IGF::OT::IGF EVALUATING INTERMITTENT DOSING OF ASPIRIN FOR COLORECTAL CANCER PREVENTION$148,159
N01 · FY2019 · CA · contact PI
OT::IGF::OT A phase I single-arm, multicenter pilot study aimed at validating y-OHPdG as a biomarker and testing the effects of Polyphenon E on its levels in patients with cirrhosis$142,319
N01 · FY2019 · CA · contact PI
Phase I trial of Endoxifen Gel Versus Placebo Gel in Women Undergoing Breast Surgery$128,664
N01 · FY2019 · CA · contact PI
IGF::OT::IGF STATIN THERAPY TO REDUCE DISEASE PROGRESSION FROM LIVER CIRRHOSIS TO CANCER$57,440
N01 · FY2019 · CA · contact PI
PHASE IIB TRIAL OF NEOADJUVANT ORAL TAMOXIFEN VERSUS TRANSDERMAL 4-HYDROXYTAMOXIFEN IN WOMEN WITH DCIS OF THE BREAST$105,004
N01 · FY2018 · CA · contact PI
OT::IGF::OT A phase I single-arm, multicenter pilot study aimed at validating y-OHPdG as a biomarker and testing the effects of Polyphenon E on its levels in patients with cirrhosis$450,103
N01 · FY2017 · CA · contact PI
Phase I trial of Endoxifen Gel Versus Placebo Gel in Women Undergoing Breast Surgery$347,069
N01 · FY2017 · CA · contact PI
IGF::OT::IGF IMMUNOGENICITY OF NONAVALENT HPV VACCINE ADMINISTERED PRIOR TO LIVING DONOR RENAL TRANSPLANTATION IN ADULT WOMEN: A PROSPECTIVE, SINGLE-ARM, MULTI-CENTER CLINICAL TRIAL$1,648,147
N01 · FY2016 · CA · contact PI
IGF::OT::IGF PHASE IIB TRIAL OF NEOADJUVANT ORAL TAMOXIFEN VERSUS TRANSDERMAL 4-HYDROXYTAMOXIFEN IN WOMEN WITH DCIS OF THE BREAST$630,210
N01 · FY2016 · CA · contact PI
IGF::OT::IGF STATIN THERAPY TO REDUCE DISEASE PROGRESSION FROM LIVER CIRRHOSIS TO CANCER$626,416
N01 · FY2016 · CA · contact PI
IGF::OT::IGF EVALUATING INTERMITTENT DOSING OF ASPIRIN FOR COLORECTAL CANCER PREVENTION$316,791
N01 · FY2016 · CA · contact PI